CRISPR Therapeutics AG $CRSP is ARK Investment Management LLC’s 8th Largest Position

ARK Investment Management LLC decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 9,786,973 shares of the company’s stock after selling 395,617 shares during the quarter. CRISPR Therapeutics comprises 3.8% of ARK Investment Management LLC’s holdings, making the stock its 8th largest position. ARK Investment Management LLC owned 10.76% of CRISPR Therapeutics worth $634,294,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of CRISPR Therapeutics by 5.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock worth $228,000 after acquiring an additional 180 shares during the last quarter. Cerity Partners LLC increased its position in CRISPR Therapeutics by 3.0% during the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock worth $318,000 after purchasing an additional 190 shares during the last quarter. Peapack Gladstone Financial Corp raised its stake in CRISPR Therapeutics by 3.0% during the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after purchasing an additional 200 shares during the period. Optiver Holding B.V. boosted its holdings in CRISPR Therapeutics by 71.4% in the 3rd quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock valued at $33,000 after purchasing an additional 210 shares during the last quarter. Finally, Ipswich Investment Management Co. Inc. grew its stake in shares of CRISPR Therapeutics by 0.9% in the 3rd quarter. Ipswich Investment Management Co. Inc. now owns 25,198 shares of the company’s stock valued at $1,633,000 after buying an additional 230 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,112 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $52.58, for a total value of $111,048.96. Following the sale, the general counsel directly owned 85,115 shares of the company’s stock, valued at approximately $4,475,346.70. This represents a 2.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Samarth Kulkarni sold 60,000 shares of the firm’s stock in a transaction on Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the completion of the sale, the chief executive officer owned 134,201 shares in the company, valued at $8,082,926.23. The trade was a 30.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 99,079 shares of company stock valued at $5,643,674. Corporate insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Robert W. Baird reduced their price target on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Citizens Jmp lowered their price target on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Chardan Capital increased their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a research note on Saturday, February 14th. Finally, TD Cowen boosted their price target on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research note on Friday, February 13th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $64.24.

CRISPR Therapeutics Stock Up 3.3%

Shares of CRSP opened at $60.00 on Thursday. The company has a market cap of $5.76 billion, a P/E ratio of -9.20 and a beta of 1.72. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The firm’s 50 day moving average price is $54.20 and its 200 day moving average price is $57.31.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Thursday, February 12th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The company’s revenue for the quarter was down 97.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.01) earnings per share. Research analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.